Epidemiology of hepatocellular carcinoma in the United States: Where are we? Where do we go?
Hashem B. El‐Serag, Fasiha Kanwal – 17 May 2014
HepG2 cells mount an effective antiviral interferon‐lambda based innate immune response to hepatitis C virus infection
Benjamin Israelow, Christopher M. Narbus, Marion Sourisseau, Matthew J. Evans – 16 May 2014 – Hepatitis C virus (HCV) exposure leads to persistent life‐long infections characterized by chronic inflammation often developing into cirrhosis and hepatocellular carcinoma. The mechanism by which HCV remains in the liver while inducing an inflammatory and antiviral response remains unclear.
Treating thrombosis in cirrhosis patients with new oral agents: Ready or not?
Nicolas M. Intagliata, Hillary Maitland, Patrick G. Northup, Stephen H. Caldwell – 15 May 2014
Hepatitis B virus: The “metabolovirus” highjacks cholesterol and bile acid metabolism
Andreas Geier – 15 May 2014
Cholangiocarcinoma development: The resurgence of bile acids
Luca Maroni, Gianfranco Alpini, Marco Marzioni – 15 May 2014
MicroRNA‐331‐3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine‐rich repeat protein phosphatase
Rui‐Min Chang, Hao Yang, Feng Fang, Jiang‐Feng Xu, Lian‐Yue Yang – 14 May 2014 – Hepatocellular carcinoma (HCC) is a highly invasive tumor with frequent intrahepatic or pulmonary metastasis, which is the main reason for high recurrence and poor survival of HCC after liver resection. However, the mechanisms for metastasis remain incompletely clear. Given that microRNAs (miRNAs) are implicated in HCC progression, we explored a potential role of miRNAs in metastasis by performing miRNA expression profiling in three subtypes of HCC with different metastatic potentials.
Valuing cure: Bridging cost‐effectiveness and coverage decisions for hepatitis C therapy
Mai T. Pho, Benjamin P. Linas – 14 May 2014
Finite entecavir therapy is a feasible alternative to indefinite therapy
Wen‐Juei Jeng – 13 May 2014
Current epidemiology of hepatitis E virus infection in the United States: Low seroprevalence in the National Health and Nutrition Evaluation Survey
Ivo Ditah, Fausta Ditah, Pardha Devaki, Calistus Ditah, Patrick S. Kamath, Michael Charlton – 13 May 2014 – Analysis of the National Health and Nutrition Evaluation Survey (NHANES) 1988‐1994 dataset found a relatively high seroprevalence (21%) of hepatitis E virus (HEV) infection in the U.S. general population. Using data obtained within the NHANES 2009‐2010 survey, where a high performance assay for HEV was used, we estimated the weighted seroprevalence of HEV infection among U.S. individuals 6 years and older. We also evaluated factors associated with HEV seropositivity.
Hepatic DNA deposition drives drug‐induced liver injury and inflammation in mice
Pedro Elias Marques, André Gustavo Oliveira, Rafaela Vaz Pereira, Bruna Araújo David, Lindisley Ferreira Gomides, Adriana Machado Saraiva, Daniele Araújo Pires, Júlia Tosta Novaes, Daniel O. Patricio, Daniel Cisalpino, Zélia Menezes‐Garcia, W. Matthew Leevy, Sarah Ellen Chapman, GermánArturo Mahecha, Rafael Elias Marques, Rodrigo Guabiraba, Vicente Paulo Martins, Danielle Gloria Souza, Daniel Santos Mansur, Mauro Martins Teixeira, M.